Rockwell Medical (RMTI) Stock Price, News & Analysis

Company Overview

Rockwell Medical, Inc. is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients. TRIFERIC is delivered via dialysate and is intended to replace iron losses that occur during the dialysis process, helping to maintain hemoglobin levels without the need for intravenous iron supplements. In addition to TRIFERIC, Rockwell Medical offers a generic injectable formulation of calcitriol, a form of vitamin D used to manage secondary hyperparathyroidism in CKD patients.

Since its founding in 1991, Rockwell Medical has conducted research, clinical development, and regulatory activities primarily in the United States. The company collaborates with specialty distributors and dialysis providers to commercialize its products and is exploring further innovations, including oral formulations of its iron therapy. Rockwell Medical’s operations are led by an experienced management team with backgrounds in nephrology, pharmaceutical development, and health-care commercialization, reflecting its commitment to improving patient outcomes in the CKD community.

Key Stats

• Today's Range: $7.07 to $7.26
• 50-Day Range: $5.19 to $7.93
• 52-Week Range: $4.89 to $21.00
• Volume: 18,087 shs
• Average Volume: 33,888 shs
• Market Capitalization: $28.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

Rockwell Medical Stock Analysis - MarketRank™

Rockwell Medical scored higher than 55% of companies evaluated by MarketBeat, and ranked 278th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Rockwell Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Rockwell Medical has a consensus price target of $20.00, representing about 178.2% upside from its current price of $7.19.

Amount of Analyst Coverage

Rockwell Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rockwell Medical are expected to grow in the coming year, from ($0.76) to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rockwell Medical is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rockwell Medical is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rockwell Medical has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.26% of the float of Rockwell Medical has been sold short.

Short Interest Ratio / Days to Cover

Rockwell Medical has a short interest ratio ("days to cover") of 1.99, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rockwell Medical has recently decreased by 89.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rockwell Medical does not currently pay a dividend.

Dividend Growth

Rockwell Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for RMTI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rockwell Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of Rockwell Medical is held by insiders.

Percentage Held by Institutions

23.31% of the stock of Rockwell Medical is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/02/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:RMTI
• CIK: 1041024
• Web: www.rockwellmed.com
• Phone: (248) 432-1362
• Fax: 248-960-9119
• Employees: 300
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Rockwell Medical: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +178.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.31 million
• Net Margins: -7.98%
• Pretax Margin: -7.98%
• Return on Equity: -15.41%
• Return on Assets: -9.62%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 3.74
• Quick Ratio: 3.43

Sales & Book Value

• Annual Sales: $69.26 million
• Price / Sales: 0.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.38 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 3,970,000
• Free Float: 3,784,000
• Market Cap: $28.54 million
• Optionable: Optionable
• Beta: 1.60